Triple-negative breast cancer: current management and future options

European Journal of Cancer, Supplement

Volumn 7, Issue 1, 2009, Pages 14-18

  Conte, PierFranco ^a   Guarneri, Valentina ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Chemotherapy; Epothilones; Metastatic breast cancer; Triple negative

Indexed keywords

ANTHRACYCLINE; AZD 2281; BEVACIZUMAB; BSI 201; CAPECITABINE; CARBOPLATIN; CETUXIMAB; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPOTHILONE DERIVATIVE; ERLOTINIB; ESTROGEN; GEMCITABINE; IMATINIB; IRINOTECAN; IXABEPILONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PROGESTERONE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST TUMOR; CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 61349093596     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(09)70005-9     Document Type: Article

References (31)

1. Dawood S., Kristine B., Hortobagyi G.N., and Giordano S.H. Prognosis of women with stage IV breast cancer by HER2 status and trastuzumab treatment: An institutional based review. J Clin Oncol 26 15S (2008) abstract 1018.
2. Bauer K.R., Brown M., Cress R.D., Parise C.A., and Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. A population-based study from the California Cancer Registry. Cancer 109 (2007) 1721-1728
3. Heitz F., Harter P., Traut A., Lueck H.J., Beutel B., and du Bois A. Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors. J Clin Oncol 26 15S (2008) abstract 1010.
4. Rouzier R., Pusztai L., Delaloge S., et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23 (2005) 8331-8339
5. Carey L.A., Dees E.C., Sawyer L., et al. The triple-negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13 (2007) 2329-2334
6. Miles D., von Minckwitz G., and Seidman A.D. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 7 Suppl 6 (2002) 13-19
7. Conte P.F., Guarneri V., Bruzzi P., et al. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer 101 (2004) 704-712
8. Fossati R., Confalonieri C., Torri V., et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16 (1998) 3439-3460
9. Sledge G.W., Neuberg D., Ingle J., et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21 (2003) 588-592
10. Joensuu H., Holli K., Heikkinen M., et al. Combination chemotherapy versus single-agent therapy as first-and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 16 12 (1998) 3720-3730
11. Alba E., Martín M., Ramos M., et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22 (2004) 2587-2593
12. Martín M., Ruiz A., Muñoz M., et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8 (2007) 219-225
13. Pivot X., Llombart-Cussac A., Martin M., et al. Clinical activity of the novel epothilone B analog, ixabepilone, in triple negative breast cancer (BC) patients. EJC Suppl 6 7 (2008) 134 Abstract 290.
14. IXEMPRA™ Kit (Ixabepilone) for injection [package insert] (2007), Bristol-Myers Squibb Company, Princeton, NJ
15. Baselga J., Gianni L., Llombart A., et al. Predicting response to ixabepilone: genomic study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer. Breast Cancer Res Treat 94 (2005) abstract 305.
16. Perez E.A., Lerzo G., Pivot X., et al. Efficacy and safety of ixabepilone (BMS0247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25 (2007) 3407-3414
17. Roché H., Yelle L., Cognetti F., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 25 (2007) 3415-3420
18. Thomas E., Tabernero J., Fornier M., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25 (2007) 3399-3406
19. Thomas E.S., Gomez H.L., Li R.K., et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycine and taxane treatment. J Clin Oncol 25 (2007) 5210-5217
20. Fumoleau P. Treatment beyond taxanes, emerging new cytotoxic agents. EJC Suppl 7 1 (2009) 8-13
21. Liedtke C., Mazouni C., Hess K.R., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26 8 (2008 Mar 10) 1275-1281
22. Hortobagyi GN, Perez E, Vrdoljak E, et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trials. ASCO Breast Cancer Symposium 2008: abstract 186.
23. Rugo H., Thomas E.S., Lee R.K., et al. Combination therapy with ixabepilone plus capecitabine is effective in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. Breast Cancer Res Treat 106 S70 (2007) abstract 6069.
24. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
25. Miles D., Chan A., Romieu G., et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26 15S (2008) abstract LBA1011.
26. Cleator S., Heller W., and Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 8 3 (2007) 235-244
27. Starita L.M., and Parvin J.D. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol 15 (2003) 345-350
28. Drew Y., and Calvert H. The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann NY Acad Sci 1138 (2008) 136-145
29. Muñoz-Gámez J.A., Martín-Oliva D., Aguilar-Quesada R., et al. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 386 (2005) 119-125
30. Carey L.A., Rugo H.S., Marcom P.K., et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 26 15S (2008) abstract 1009.
31. O'Shaughnessy J., Weckstein D., Vukelja S.J., et al. Randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 106 (2007) abstract 308.